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Genetic epidemiology of diabetes
M. Alan Permutt,1 Jonathon Wasson,1 and Nancy Cox2
1Department

of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA.
2Department of Human Genetics, The University of Chicago, Chicago, Illinois, USA.

Conventional genetic analysis focuses on the genes that account for specific phenotypes, while traditional epidemiology is more concerned with the environmental causes and risk factors related to traits. Genetic epidemiology
is an alliance of the 2 fields that focuses on both genetics, including allelic variants in different populations, and
environment, in order to explain exactly how genes convey effects in different environmental contexts and to arrive
at a more complete comprehension of the etiology of complex traits. In this review, we discuss the epidemiology
of diabetes and the current understanding of the genetic bases of obesity and diabetes and provide suggestions for
accelerated accumulation of clinically useful genetic information.
Definition of the problem
Diabetes is a metabolic condition in which the body fails to produce enough insulin. Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing β cells, which leaves the
patient dependent on insulin injections for survival (1) T2D, formerly known as adult-onset diabetes, occurs when impaired insulin
effectiveness (insulin resistance) is accompanied by the failure to
produce sufficient β cell insulin. Patients can be placed on regimens
to reduce weight or manage diet or treated with medication and,
less often, insulin injections. This latter form of diabetes accounts
for as much as 95% of cases. Gestational diabetes is another form of
diabetes, defined as a state of glucose intolerance during pregnancy
that usually subsides after delivery but has major implications for
subsequent risk of T2D, as pregnancy serves as an “environmental”
stressor that reveals a genetic predisposition. Other less common
forms of diabetes include the rare, genetically determined disease
maturity onset diabetes of the young (MODY), diabetes resulting
from surgery, and other illnesses that constitute only 1–5% of cases.
Based on plasma glucose measurements, 2 conditions have been
identified with increased risk of the disease (2): (a) impaired glucose
tolerance (IGT) is defined as hyperglycemia intermediate between
normal and diabetic levels following a glucose load; (b) impaired
fasting glucose (IFG), like IGT, is associated with increased cardiovascular disease (CVD) and future diabetes. Because complications
of diabetes may develop years before overt disease, many consider
the disease part of a cluster of CVD risk factors that include hypertension, hyperinsulinemia, dyslipidemia, visceral obesity, hypercoagulability, and microalbuminuria. This collection of risk factors is
also known as the metabolic syndrome (3, 4).
While insulin therapy can reverse many of the metabolic disturbances, and numerous improvements in management have been
introduced (5), the disease has reached epidemic proportions.
According to the WHO (6), it is likely to be one of the most substantial threats to human health in the 21st century.

Nonstandard abbreviations used: ASP, affected sibling pair; CVD, cardiovascular
disease; DZ, dizygotic; IGT, impaired glucose tolerance; IRAS, Insulin Resistance Atherosclerosis Study; MODY, maturity onset diabetes of the young; MZ, monozygotic;
SNP, single nucleotide polymorphism; T1D, type 1 diabetes; T2D, type 2 diabetes;
VNTR, variable number of tandem repeats.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 115:1431–1439 (2005).
doi:10.1172/JCI24758.
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Prevalence
The prevalence of diabetes in the United States has risen 40%, from
4.9% in 1990 to 6.9% in 1999 (7). A breakdown of the prevalence of
diabetes by state from 1990 through 2001 and of obesity by state
from 1991 through 2003 is shown in Figure 1, A and B, respectively (8, 9). The disease affects various groups differently, occurring
10 times more commonly in those older than 65 years compared
with those younger than 45 years. Minority racial groups including
Hispanics, African Americans, and Native Americans are generally
affected at a rate 2–4 times that for white individuals. The recent
increased prevalence has also been noted in children and adolescents, where T2D may now occur more commonly than T1D (10).
The estimated lifetime risk of developing diabetes for individuals
born in the United States in 2000 is 33% for males and 39% for
females (7). It is highest among Hispanic females, at 53%. Diabetes
is associated with large reductions in life expectancy, on the order
of 11 years in males diagnosed at age 40. While an estimated 18.2
million persons had diabetes in the United States in 2002 (11), diabetes worldwide has been estimated to affect 151 million persons,
and that number projected to increase to 324 million by 2025 (2).
The medical burden of diabetes
The burden of diabetes is to a large extent the consequence of
macrovascular and microvascular complications of the disease,
which result in large increases in morbidity and mortality. For
example, the prevalence of ischemic heart disease is 2–14 times
the rate in age-matched nondiabetics (12). Diabetic retinopathy
is the chief cause of blindness in the US. In 2000, diabetic renal
disease accounted for 40% of new cases of end-stage renal disease,
and diabetics are the largest group receiving dialysis (more than
50% of all cases) and renal transplants (approximately 25%). Lower
extremity disease resulting from a combination of peripheral vascular disease and neuropathy causes an increase in lower extremity
amputations. While improved glycemic control has been shown
to reduce the incidence of microvascular complications, episodes
of severe symptomatic hypoglycemia were 3 times higher in those
receiving intensive insulin management therapy (13). Along with
experiencing physical and cognitive disabilities, adults with diabetes have an age-adjusted mortality rate estimated to be twice
that of nondiabetics (12). Risk factors for CVD, including systolic
hypertension, elevated cholesterol levels, and cigarette smoking,
independently predict CVD mortality, and any 1 risk factor affects
outcomes more in persons with diabetes (14).
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Figure 1
(A) Diabetes trends among adults in the US. *Includes gestational diabetes. Adapted from ref. 8. (B) Obesity trends among US adults.
**BMI ≥ 30 (about 30 pounds overweight for a 5-ft 4-in. individual). Adapted from ref. 9.

Although increase in diabetes prevalence occurs mostly in middle-aged and older adults, there is strong evidence of an increase
in the prevalence of T2D in children (10). For example, in Japan
the incidence in school children (6–15 years old) has doubled over
a 20-year period, such that T2D is now more common than T1D
(15). In the US, up to 45% of the newly diagnosed diabetics in the
pediatric age group have T2D (10). This rise in diabetes rates in
children reflects, at least in part, the growing prevalence of obesity
in this age group (16).
Direct medical expenditures and lost productivity due to diabetes were estimated to cost the US $132 billion in 2002 (17). The
per capita expenditures were twice those for individuals without
the disease. While the prevalence of diagnosed diabetes is less than
5% of the population, almost $1 of every $5 spent on health care in
the US is for patients with diabetes. As the prevalence of diabetes
increases with age, and because of the increasing diabetes-prone
populations, it has been estimated that the number of diagnosed
cases will increase. Thus the projected total cost in 2002 dollars
could be as high as $192 billion by 2020.
Etiology of the diabetes epidemic
The sudden increase in diabetes in the last few years is due not to
genetic factors but rather to the increase in obesity. This phenomenon is currently being documented in Africa, where the incidence
of diabetes is rising with urbanization. The incidence is also rising
among Africans who have immigrated to the US (18, 19). Epidemiological studies have regularly shown the relationship between
diabetes and obesity, mediated in part by nutritional and lifestyle
factors (20, 21). The most common measure of obesity, body mass
index (BMI), combines measurements of height and weight. People with a BMI greater than 25 are said to be overweight, while
those with a BMI greater than 30 are defined as obese (22). The
Nurses Health Study showed that the risk for developing diabetes
increased sharply for individuals observed as having a BMI greater
than 23 for 16 years and was increased 20-fold for those with a
BMI greater than 30 (18). In a recent study of measures of obesity
and CVD risk factors in Australian adults, the prevalence of T2D
rose from 5% in normal-weight to 16% in obese males; of hypertension, from 20% to 49%; and of dyslipidemia, from 18% to 61%, with
even higher prevalence in females (23).
1432
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The molecular and physiological relationships between obesity
and diabetes are not fully understood, and this subject is an area of
intense investigation (see ref. 22 for review). The “thrifty genotype”
hypothesis was proposed to account for a genetic advantage of
accelerated fat deposition during times of restricted availability of
calories, which leaves individuals faced with harmful consequences given the abundant food supply and reduced levels of physical
activity in developed countries today (24). Noting an association
between low birth weight and increased incidence of diabetes in
later life, Hales and Barker have hypothesized that intrauterine malnutrition result in reduced birth weight and to subsequent changes
leading to disease in adults (25, 26). This phenomenon, also known
as the “thrifty phenotype” hypothesis, proposes that fetal malnutrition results in impaired pancreatic β cell development and insulin
resistance. Offspring are subsequently more prone to diabetes and
the metabolic syndrome when exposed to abundant nutrition later
in life. In this regard, the increased prevalence of T2D in offspring
of diabetic mothers may be a consequence of environmental factors operating on a genetic background, i.e., an altered intrauterine
environment superimposed on a genetic predisposition in the fetus.
While epidemiological studies have confirmed these observations,
virtually nothing is known of their mechanisms, and this is an
active area of investigation (27). If the relationship between obesity
and diabetes could be understood, or obesity effectively prevented
with treatment, then therapies directed at these mechanisms might
curtail the increasing incidence of the disease.
The relationship between obesity and diabetes has been extensively studied in inbred strains of mice (28). Mice from a single
inbred strain fed a high-fat diet all became insulin resistant, yet
only about half became both obese and diabetic. Interestingly, 10%
became diabetic but resisted obesity, and 10% became obese but
not diabetic. The mechanisms responsible are unlikely to be purely
genetic, and the results are consistent with the hypothesis that epigenetic changes and stochastic factors contribute to the phenotypic diversity. More recently, ER stress was shown to be the etiology
of obesity-induced insulin resistance and diabetes in experimental
mouse models, and this mechanism promises to be a rewarding
area of investigation in the near future (29). If the degree of ER
stress varies among mice, then perhaps this could explain the phenotypic differences in mice that are genetically identical.
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As it has long been noted that levels of FFAs are increased in
obese individuals, their accumulation in skeletal muscle has been
proposed to compete with circulating glucose resulting in hyperglycemia, hyperinsulinemia, and ultimately insulin resistance
(30). Recently, using magnetic resonance spectroscopy in patients
with obesity and/or T2D, Shulman et al. have shown a reduction
in the rate of insulin-stimulated glucose metabolism secondary
to reduced muscle glycogen synthesis, associated with a blunted
increase in intramuscular glucose 6 phosphate relative to concentration in insulin-resistant offspring of diabetic parents compared
to control individuals (31, 32). Increased intracellular fatty acid
metabolites were found to result in decreased insulin signaling
and impaired glucose transport. Other factors contributing to the
insulin resistance of obesity include the tendency to store fat in
the abdominal region as opposed to the extremities and defects in
adipocyte fatty acid metabolism and mitochondrial fatty acid oxidation. While impaired mitochondrial activity in insulin-resistant
offspring of patients with T2D has been observed (33), the genetic
basis for reduced mitochondrial biogenesis has not been elucidated. Reduced mitochondrial activity results in reduced energy
expenditure, obesity, increased intramuscular fatty acid accumulation, and insulin resistance and has therefore been incorporated
into the thrifty gene hypothesis (32).
Heritability of diabetes
The recent increased prevalence of obesity and diabetes must be
largely attributable to changes in nongenetic risk factors. Yet environmental aspects must certainly accelerate the disease in those
with genetic predisposition. There is a clear need to understand
the genetic basis for the regulation of food intake, energy expenditure, and variations in energy balance in various individuals.
In the long run, it may be more beneficial to develop treatments
based on these genetic mechanisms than to rely on the use of will
power to modify lifestyle. Moreover, different aspects of environment may be more critical in different subsets of individuals. We
know from the natural history of diabetes complications that
when patients are first diagnosed, there may already be marked
progression of microvascular and macrovascular complications
(34). The overwhelming majority of obese individuals have insulin
resistance, yet only 5–10% develop pancreatic β cell failure and
diabetes. Discovering the genetic risk factors for the disease will
likely have many positive consequences.
The familial occurrences of both T1D and T2D have been long
noted. A sibling’s risk of developing T1D (5–10%) is perhaps 12- to
100-fold greater than the risk in the general population (0.1–0.4%)
(35). Concordance in monozygotic (MZ) twins has been consistently shown to be greater than that in dizygotic (DZ) twins (36).
For T2D, the concordance among MZ twins has been observed to
be 50–92%, higher than the 37% concordance in DZ twins (36).
Thus while the relative risk to a sibling, a measure of the genetic
contribution, is considerably greater for T1D than for T2D, the
concordance and absolute risk are substantially greater for T2D,
which perhaps underscores the importance of the environmental
contribution to the latter (37).
Quantitative phenotypes related to glucose homeostasis are also
known to be heritable (38). In families with an increased genetic
susceptibility to T2D, heritability estimates for β cell function
and features of the insulin resistance syndrome of 72% and 78%,
respectively, were calculated (39). The heritability of other features of the insulin resistance syndrome, including BMI, blood
The Journal of Clinical Investigation

pressure, and serum lipid and insulin sensitivity levels, was also
estimated to be high. Evidence for heritability of these metabolic phenotypes was reported in studies of Pima Indians (40) and
nondiabetic Japanese Americans (41); in the Insulin Resistance
Atherosclerosis Study (IRAS) among family members of African
American and Hispanic heritage (42); and in a study of the familial aggregation of the amount and distribution of subcutaneous
fat and responses to exercise training in the HERITAGE Family
Study (43). These studies strongly support the role of both genetic and environmental factors in the etiology of diabetes and the
insulin resistance syndrome.
The value of monogenic subtypes of diabetes
Recent reviews provide detailed appraisals of both linkage and association studies in diabetes (38, 44). We focus here on the patterns
that have emerged in the search for genetic risk factors for diabetes.
Linkage mapping, positional cloning, and candidate gene studies
have been most successful in the forms of diabetes with the simplest genetic models. Early studies characterizing diabetes resulting
from mutations in insulin (INS) and insulin receptor (45) genes as well
as the mitochondrial genome (46) provided important insights into
glucose homeostasis, but it is the studies on MODY that provide
the classic example of the successful application of genetics to diabetes (47, 48). Linkage mapping studies on MODY were quite successful, and within a few years, a combination of positional cloning
and studies of positional candidate genes led to the identification
of glucokinase (GCK) and hepatocyte nuclear factors 4α and 1α (HNF4A
and TCF1) as genes in which a single mutation could lead to the
complex metabolic phenotype of diabetes (see ref. 49 for a recent
review). GCK is the rate-limiting enzyme in glucose metabolism;
HNF4A and TCF1 are transcription factors expressed in a variety of
tissues, including the liver and pancreas where they work in a transcription regulatory network to regulate the expression of genes
involved in glucose transport and metabolism (49).
Once these genes had been implicated in MODY, a number of
other transcription factors within the same regulatory network
were also found to be MODY genes. As noted above, mutations
in MODY genes, at the INS and INS receptor genes, or in the mitochondrial genome collectively account for only a small proportion
of diabetes — about 1–5% (50). However, the monogenic forms of
diabetes provide important insights into how we should be thinking about the genetic components of a phenotype as broad and
metabolically complex as that of diabetes. The genes in which a
single mutation is sufficient to generate this phenotype play an
absolutely central role in glucose homeostasis (e.g., INS, the INS
receptor, GCK) or are capable of affecting the regulation of many
genes that act within this overall pathway (e.g., transcription factors). From these studies we learned that glucose homeostasis is
a balance between insulin production, determined by β cell mass
and/or function, and insulin action. Some of the genes that have
been shown to affect these processes either in humans or experimental animals are illustrated in Figure 2.
The general observations on the genes implicated in monogenic
forms of diabetes fit well within the emerging theories for how biological networks might be expected to perform and suggest that
a systematic application of network theory to the metabolic and
regulatory pathways underlying glucose homeostasis may provide
a fruitful avenue for prioritizing genes for future studies. Recent
research suggests that a scale-free topology is a nearly universal feature of networks, whether we are considering air traffic patterns,
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Figure 2
Diabetes results from an imbalance between the
insulin-producing capacity of the islet β cell and
the requirement for insulin action in insulin target
tissues such as liver, adipose tissue. and skeletal
muscle. Some of the many genes that have been
shown or could possibly contribute to the imbalance are illustrated.

network theory with even the information we
already have about the pathways implicated
in glucose homeostasis, we could predict that
genes/proteins located at hubs that are the
most highly interconnected are those most
vulnerable to degrading the overall system.
Thus, genetic variation at hub genes may be
more likely to lead to detectable perturbations in glucose homeostasis. While we might
use network theory to prioritize genes for
study simply based on the relative connectedness of the genes at the hubs in the networks, it might also be useful to overlay such
an analysis on existing information we have
about potential genetic risk factors for diabetes via linkage mapping or linkage disequilibrium mapping studies. A similar strategy
was recently applied in studies of Alzheimer
disease, with promising results (54).

the Internet, or biological pathways in complex organisms (51–53).
A network with scale-free topology is characterized by that there
is a relatively small number of hubs that have substantially more
connections than average, along with a much larger number of
nodes that have a very limited number of other connections. Such
networks can be very stable and robust but are most vulnerable at
those hubs that have the most connections to other nodes. Using
1434
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Genetic studies on T1D
Genetic linkage studies of T1D and T2D have
been quite variable, spanning the spectrum of
results generally observed for disorders with
complex inheritance. T1D is unique among
complex disorders in the magnitude of the
familial risk attributable to a single locus,
HLA. While HLA was originally implicated
through association studies as a candidate
gene (55), the magnitude of the evidence for
linkage at HLA in T1D is larger than has been
observed for a linkage in any other complex
disorder, although some other autoimmune
disorders also have strong evidence for linkage in the HLA region (56). Because of the
major contribution of HLA to the familial
risk of T1D, identification of the other genetic risk factors may be more akin to identifying modifier loci for monogenic disorders
than identifying primary susceptibility loci
for complex disorders. Indeed, the non-HLA
genes that have been reproducibly characterized as T1D susceptibility loci have been identified largely through candidate gene studies.
Evidence for linkage at the non-HLA loci implicated in T1D has
been uneven at best. For example, the very common class I alleles
at INS variable number of tandem repeats (VNTR) are significantly
overtransmitted from parents heterozygous for this allele to offspring affected with T1D (57). There was no evidence for linkage
of the INS region to T1D in 100 affected sibling pair (ASP) families
(58) and only modest evidence in more than 200 families (59). In a
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large sample (767 families) including ASP families from both the
US and the United Kingdom, there was significant evidence for
linkage near INS (60). Similarly, initial evidence for linkage near
CTLA4, another locus with support for affecting susceptibility to
T1D through association studies, was detected in some individual
samples, but little evidence for linkage in the region of CTLA4 was
found in larger, combined samples (60). Finally, PTPN22, a locus
recently implicated as a candidate gene in T1D (61), rheumatoid
arthritis (62), and systemic lupus erythematosus (63), shows little
evidence for linkage to T1D even in relatively large samples (60).
Genetic studies on T2D
The success of linkage mapping for T2D has been similar to that
observed for other complex disorders, which has been, regrettably,
quite limited. More than 25 genome-wide screens have been conducted on samples from all over the world (for review, see ref. 44).
Despite the number of studies, there are only a few regions with
replicated evidence for linkage: 1q, 3q, 8p, 10q, 12q, and 20q. Even
in these regions, however, evidence for linkage is far from universal
(3–7 of the more than 25 studies show nominally significant evidence for linkage), peaks are broad, and it is unlikely that all studies with linkage signal in a given region reflect the contribution of
the same susceptibility genes.
Factors contributing to the complexity of analysis
Why has linkage mapping been relatively unsuccessful in localizing
susceptibility genes for T1D and T2D in even relatively large, combined data sets? The complexity of the underlying genetic model
is clearly a contributing factor. We have almost certainly underestimated the number of different genetic risk factors for both
disorders and overestimated the magnitude of effect that might
be expected for any one of these loci, excepting, perhaps, HLA in
T1D. It might be argued that the initial success with HLA in T1D,
the first susceptibility gene successfully linked to a complex disorder, encouraged us to establish a series of unrealistic expectations
for how genetic risk factors contribute to diabetes and other complex disorders. Among the complexities of the genetic models for
complex disorders that are likely to contribute to the difficulties
in linkage mapping are gene-gene and gene-environment interactions. Such interactions are difficult to accommodate in primary
linkage mapping studies and yet are a requisite part of the definition of a complex trait. It is not clear whether these problems
could be solved by increasing either the sample sizes for linkage
studies or the number of phenotypes examined. In particular, the
failure to adequately measure and account for nongenetic factors
affecting risk of diabetes almost certainly has reduced our ability
to successfully map genetic risk factors.
The diagnosis of diabetes has long been standardized and is both
reliably and inexpensively achieved with a simple blood test. These
factors contributed substantially to making diabetes the first complex disorder to be widely studied using genetic tools. But the diagnosis of diabetes is designed to focus on the clinical consequences
of elevated blood glucose levels rather than the underlying genetic
liability to this very complex metabolic disease. The simple dichotomous diagnosis masks a tremendous amount of clinical heterogeneity, and it is likely that the genetic heterogeneity of diabetes
is at least as great as the clinical heterogeneity. Thus, efforts to
specify more genetically homogeneous samples according to clinical characteristics might also be fruitful. For example, stratifying
T1D families for linkage analyses according to antibody positivThe Journal of Clinical Investigation

ity, or patients with T2D by BMI, might lead to more consistent
and reproducible results in linkage mapping studies. Additionally,
analysis of quantitative traits that may be related to the primary
dichotomous trait of T2D, such as insulin resistance, β cell mass
and performance, BMI and other features of the metabolic syndrome, may lead to the identification of genes contributing to risk
of T2D (64). Several such studies have been already been initiated
(see ref. 65 for review), including a recent IRAS study of quantitative traits in African American and Hispanic families (66), and the
results point to promising genomic regions, though no causative
genes have yet been identified. In this regard, use of animal models could help in gene identification, as syntenic regions are being
evaluated in congenic strains in order to narrow regions conveying
genetic risk for T2D, as, for example, in obese mice (67). We must
also recognize, however, that the quantitative phenotypes that we
now know how to measure easily are not necessarily the phenotypes best able to characterize the genetic liability to T2D.
Emerging patterns and implications for study design
The patterns emerging from the linkage and association studies
that have identified genetic risk factors for diabetes offer intriguing insights into the challenges we face in improving our study
designs. Some of the factors are common but so low risk that
they would be quite difficult to detect in linkage mapping studies. For example, the allele increasing risk of T2D at PPARG has
a frequency of 0.85–0.95 in most of the world’s populations (68)
and is associated with very modest increase in risk. Similarly, the
class I alleles (or polymorphisms in linkage disequilibrium with
them) increasing risk for T1D at the INS VNTR are found at very
high frequency in populations of European and Asian descent
(0.70–0.85), but they increase risk only modestly (69). There are
rarer amino acid polymorphisms that have been reliably associated
with diabetes. For example, the allele increasing risk of T2D at the
T504A polymorphism at CAPN10 ranges in frequency from 0.04 to
0.16 (70), and the allele increasing risk of T1D at the R620W polymorphism at PTPN22 ranges in frequency from 0.08 to 0.14 (69).
But many of the polymorphisms associated with increased risk of
diabetes identified to date are not amino acid polymorphisms. The
variation at CTLA4 implicated in T1D appears to affect splicing
(71), while variation at the INS VNTR (69), at CAPN10 (72), and
at HNF4A (73, 74) (as discussed in more detail below) may affect
gene expression. Linkage mapping, even with very large samples,
will miss many of these risk factors. Similarly, genome-wide association mapping focused exclusively on common haplotypes will
miss many of the rarer risk alleles. Strategies targeting known
amino acid polymorphisms will miss rare, unknown susceptibility
variants and may not detect the effects of the more common noncoding sequence polymorphisms either. Until it becomes clearer
whether there will be a predominant frequency spectrum or polymorphism type in the genetic variation affecting susceptibility to
diabetes (whether type 1 or 2), it seems prudent to adopt strategies
that enable detection of susceptibility alleles with a wide range of
frequencies and effects. Some known genes associated or linked
with diabetes are listed in Table 1 (61, 70, 73, 74, 90–117).
Sample size for low-risk genes associations
Identification of susceptibility alleles for T1D, outside the HLA
locus, and T2D, whether through positional cloning or in the context of studies on functional candidates, has been challenging. Initial positive results are usually only inconsistently replicated. For
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Table 1
Some known genes associated or linked with diabetes by replication in at least 2 studiesA
Type

Gene

Gene name

Function

SNP or allele or locus or marker

Refs.

MODY 1
MODY 2
MODY 3

HNF4A
GCK
TCF1

Hepatocyte nuclear factor 4 α
Glucokinase
Hepatocyte nuclear factor 1α

Transcription factor
Glucose metabolism
Transcription factor

90, 91
92, 93
93, 94

MODY 4
MODY 5
MODY 6

IPF1
TCF2
NEUROD1

Insulin promoter factor 1
Hepatocyte nuclear factor 1β
Neurogenic differentiation 1

Transcription factor
Transcription factor
Transcription factor

HLA
INS

Human leukocyte antigen
Insulin

Immune system regulation
Involved in numerous aspects
of metabolism
Immune system regulation
Immune system regulation

Mutations in 13 families
130 different mutations described
120 different mutations described
in all racial ethnic backgrounds
Rare mutations; 1 family described
Rare mutations
Mutations described in 2 families
with autosomal dominant form
Variants in multiple genes
VNTR

99, 100
99, 101

T17A
SNP C1858T

102, 103
61, 104

SNPs in various exons

105, 106

Various intronic SNP haplotypes
G40S

70, 107
108, 109

Microsatellite in 3′ end of gene
E23K

110, 111
112, 113

P12A

114, 115

P2 promoter SNPs
XbaI(–) restriction site

73, 74
116, 117

T1D
T1D
T1D
T1D
T2D
T2D
T2D
T2D
T2D
T2D
T2D
T2D
Awith

CTLA4 Cytoxic T-lymphocyte–associated protein 4
PTPN22
Protein tyrosine phosphate,
non-receptor type 22
ATP-binding cassette,
Regulator of potassium channels
ABCC8
subfamily C; sulfonylurea receptor
and insulin release
CAPN10
Calpain 10
Protease
GCGR
Glucagon receptor
Controls hepatic glucose production
and insulin secretion
GCK
Glucokinase
Glucose metabolism
KCNJ11
Potassium inwardly-rectifying
Regulation of insulin secretion
channel, subfamily J, member 11
PPARG
Peroxisome proliferator-activated
Transcription factor
receptor γ
HNF4A
Hepatocyte nuclear factor 4 α
Transcription factor
SLC2A1
Glut 1
Glucose transporter
the exception of MODY 4 and MODY 6.

example, conflicting results of different studies on the Pro12Ala
polymorphism in the PPARG2 gene were resolved by analysis of
large family and case control samples; and a meta-analysis of all
published studies further demonstrated that this polymorphism
does affect risk of T2D, but only to a small degree (68). Similarly
the E23K polymorphism in the Kir6.2 subunit of the ATP-regulated potassium channel has been shown by meta-analysis to contribute a small but significant risk to the disease in the populations
studied (75, 76). Except for HLA in T1D, the susceptibility alleles
for T1D and T2D quite modestly affect risk of disease, which
mandates the study of large sample sizes. This argues for large
collaborative studies, wherein sample sizes will be on the order of
thousands and replication will be conducted during the primary
investigation rather than through the time-consuming process of
publication of multiple individual studies.
Investigating potential regulatory regions
of candidate genes through haplotype-tagged SNPs
While every nonsynonymous coding single nucleotide polymorphism (SNP) in candidate genes should be tested for possible
contribution to disease susceptibility, 2 recent studies highlight
the importance of conducting association studies with markers
in potential regulatory regions. Earlier studies with SNPs in or
near the coding region of HNF4A, a gene previously shown to be
mutated in rare cases of MODY (77), had yielded no association
with T2D (78). More recently, it was discovered that a second promoter exists 40 kb upstream of the gene (79, 80) and that SNPs
in the region of this second promoter and in other parts of the
1436
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noncoding sequence of HNF4A were associated with T2D in Ashkenazi Jews (74) and in a sample in Finland (73). Results of followup studies in other populations may provide some confirmation
of the association between T2D and noncoding SNPs at HNF4A
and its regulatory regions (81), but we should not be surprised if
some studies in even large replication samples fail to observe associations and should be equally prepared for the possibility that not
all studies will identify the very same polymorphisms as showing
association. The nature of regulatory variation virtually insures
that effects attributable to one polymorphism might be attenuated by effects of a second polymorphism — thus, the cumulative
effects of regulatory variants may be poorly predicted by the marginal effects measured for any individual variant.
DNA diagnostics and pharmacogenetics in clinical trials
The use of genomic tools provided by the Human Genome Project offers the opportunity to identify individuals at risk, classify
subtypes of the disease, choose therapy based on more accurate
diagnosis (82), more precisely delineate the environmental factors
that contribute to the onset and progression of the disease and its
complications, and monitor responses to therapy (83, 84). Recently,
genetic information was applied to clinical diabetes management
in a randomized crossover trial of gliclazide, an agent affecting
insulin secretion, and metformin, an agent that enhances insulin
action. Compared with patients with typical T2D, patients with
diabetes caused by a particular MODY mutation in TCF1 (85) had
a 4- to 5-fold greater response to gliclazide than to metformin.
Another example was the recent finding of heterozygous mutations
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in the ATP-sensitive K+ channel subunit of the Kir6.2 gene in 7 of
11 patients with neonatal diabetes (86). This gene plays a critical
role in glucose-stimulated insulin secretion. Remarkably, several
patients who previously required insulin injections were taken off
insulin and treated with oral medication, which again illustrates
the efficacy of pharmacogenetics for treatment of some diabetics.
A large number of clinical trials for both T1D and T2D are currently being conducted. The Type 1 Diabetes Genetics Consortium (T1DGC; http://www.t1dgc.org) will organize international
efforts to identify genes that determine an individual’s risk of T1D
through the identification of 2,500 new families with 2 or more
affected siblings. To explore approaches to treatment of T2D in
youth, the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth; http://www.TODAYstudy.org) study will enroll
750 children and teenagers that have recently been diagnosed with
T2D. Participants will be assigned to groups for treatment aimed
at weight reduction and increasing physical activity. The Look
AHEAD (Action for Health in Diabetes) trial is a multicenter,
randomized clinical trial that will examine the consequences of a
lifestyle intervention designed to achieve and maintain weight loss
over the long term through decreased caloric intake and increased
exercise in 5,000 obese patients with T2D. The National Heart,
Lung, and Blood Institute–led Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial is designed to test the effects of
glycemia and blood pressure control on major CVD events and
the use of fibrate treatment to increase HDL cholesterol and lower
triglycerides (http://www.accordtrial.org/public/index.cfm). The
Bypass Angioplasty Revascularization Investigation 2 Diabetes
(BARI 2D) trial (http://www.bari2d.org) addresses questions about
therapy in adults with T2D and stable CAD who might be candidates for revascularization. These studies represent ideal opportunities to incorporate DNA diagnostic testing and assessment of
variable responses to therapeutic interventions.
Large prospective cohort study for the effects of genes
and environment on diabetes
While case-control studies have much to offer for the assessment of
the interactions between genes and environmental factors, Francis
Collins noted that clinically diagnosed cases may represent only the
more severely affected individuals with the disease and highlighted
the difficulties of selecting an unbiased control group (87). To more
accurately quantify genetic contribution and population-wide risk,
he proposed prospective, population-based cohort studies (88). In a
1. Porte, D., Sherwin, R.S., and Baron, A. 2003. Ellenberg & Rifkin’s diabetes mellitus. McGraw-Hill. New
York, New York, USA. 1047 pp.
2. Zimmet, P., Shaw, J., and Alberti, K.G. 2003. Preventing Type 2 diabetes and the dysmetabolic
syndrome in the real world: a realistic view. Diabet.
Med. 20:693–702.
3. Misra, A., and Vikram, N.K. 2004. Insulin resistance syndrome (metabolic syndrome) and obesity
in Asian Indians: evidence and implications. Nutrition. 20:482–491.
4. Meigs, J.B., et al. 2003. Prevalence and characteristics of the metabolic syndrome in the San Antonio
Heart and Framingham Offspring Studies. Diabetes. 52:2160–2167.
5. Hirsch, I.B. 2004. Blood glucose monitoring technology: translating data into practice. Endocr. Pract.
10:67–76.
6. WHO. Diabetes program. http://www.who.int/diabetes/en/.
7. Narayan, K.M., Boyle, J.P., Thompson, T.J.,
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Unanswered questions and future opportunities
Many of the questions raised here cannot yet be answered. Will
genome-wide association studies work in a way that genome-wide
linkage mapping studies did not? Will the identification of more
homogeneous subsets of patients be the key to making any real
headway in either association or linkage mapping studies? Are nongenetic risk factors largely uniform, or are they perhaps as variable
as genetic risk factors? Will we really get improvement in understanding with a “better” version of more of the same, or do we need
to move to something qualitatively different? Genomic technology
is advancing rapidly, and larger, higher-powered studies will soon
be possible — these studies should allow us to address these questions. The challenge now is for clinical scientists to provide wellcharacterized populations with carefully recorded phenotypic and
environmental data. This challenge will extend to the acquisition
of new organizational skills to collate these data from many centers
and provide integration with the large volume of genetic data soon
to be generated (89). The opportunities are great for future diabetes
genetic epidemiology research to provide clinically useful information, the most vital goal of the Human Genome Project.
Acknowledgments
The authors wish to acknowledge NIH grants DK049583 (“Metabolic Basis of NIDDM: A Sib Pair Analysis”) and DK58026 (“International Type 2 Linkage Consortium”); and Ping An, Richard Bergman,
Ernesto Bernal-Mizrachi, Rudy Leibel, and Mike Province for helpful discussions and suggestions regarding the manuscript. Corentin
Cras-Meneure helped with illustrations as well as discussions.
Address correspondence to: M. Alan Permutt, Washington University School of Medicine, 660 South Euclid Avenue, Campus
Box 8127, St. Louis, Missouri 63110-1010, USA. Phone: (314) 3628680; Fax: (314) 747-2692; E-mail: apermutt@im.wustl.edu.

Sorensen, S.W., and Williamson, D.F. 2003. Lifetime risk for diabetes mellitus in the United States.
JAMA. 290:1884–1890.
8. Centers for Disease Control and Prevention. 2005.
Diabetes maps. Maps — diabetes and gestational
diabetes trends among adults in the united states,
behavioral risk factor surveillance system: 1990,
1995 and 2001. http://www.cdc.gov/diabetes/
statistics/maps/index.htm.
9. Centers for Disease Control and Prevention. 2005.
Overweight and obesity: obesity trends: U.S. obesity trends 1985–2003. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm.
10. Alberti, G., et al. 2004. Type 2 diabetes in the
young: the evolving epidemic: the international
diabetes federation consensus workshop. Diabetes
Care. 27:1798–1811.
11. Centers for Disease Control and Prevention. 2005.
National diabetes fact sheet: national estimates
on diabetes. http://www.cdc.gov/diabetes/pubs/
estimates.htm#prev.

The Journal of Clinical Investigation

http://www.jci.org

Volume 115

12. Engelgau, M.M., et al. 2004. The evolving diabetes burden in the United States. Ann. Intern. Med.
140:945–950.
13. The Diabetes Control and Complications Trial
Research Group.1993. The effect of intensive
treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.
329:977–986.
14. Stamler, J., Vaccaro, O., Neaton, J.D., and Wentworth, D. 1993. Diabetes, other risk factors, and
12-yr cardiovascular mortality for men screened in
the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:434–444.
15. Kitagawa, T., Owada, M., Urakami, T., and Yamauchi, K. 1998. Increased incidence of non-insulin dependent diabetes mellitus among Japanese
schoolchildren correlates with an increased intake
of animal protein and fat. Clin. Pediatr. (Phila.)
37:111–115.
16. Bhargava, S.K., et al. 2004. Relation of serial chang-

Number 6

June 2005

1437

Downloaded on June 9, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/24758

review series
es in childhood body-mass index to impaired glucose tolerance in young adulthood. N. Engl. J. Med.
350:865–875.
17. Hogan, P., Dall, T., and Nikolov, P. 2003. Economic
costs of diabetes in the US in 2002. Diabetes Care.
26:917–932.
18. Motala, A.A., Omar, M.A., and Pirie, F.J. 2003. Diabetes in Africa. Epidemiology of type 1 and type 2
diabetes in Africa. J. Cardiovasc. Risk. 10:77–83.
19. Rotimi, C.N., et al. 2001. In search of susceptibility
genes for type 2 diabetes in West Africa: the design
and results of the first phase of the AADM study.
Ann. Epidemiol. 11:51–58.
20. Zimmet, P.Z. 1999. Diabetes epidemiology as a tool
to trigger diabetes research and care. Diabetologia.
42:499–518.
21. Hu, F.B., et al. 2001. Diet, lifestyle, and the risk of
type 2 diabetes mellitus in women. N. Engl. J. Med.
345:790–797.
22. Speakman, J.R. 2004. Obesity: the integrated roles
of environment and genetics [review]. J. Nutr. 134(8
Suppl.):2090S–2105S.
23. Dalton, M., et al. 2003. Waist circumference, waisthip ratio and body mass index and their correlation
with cardiovascular disease risk factors in Australian adults. J. Intern. Med. 254:555–563.
24. Neel, J.V. 1999. The “thrifty genotype” in 1998
[review]. Nutr. Rev. 57:S2–S9.
25. Hales, C.N., et al. 1991. Fetal and infant growth
and impaired glucose tolerance at age 64. BMJ.
303:1019–1022.
26. Hales, C.N., and Barker, D.J. 2001. The thrifty phenotype hypothesis. Br. Med. Bull. 60:5–20.
27 NIH, Office of Extramural Research. 2003. The fetal
basis of adult disease: role of the environment [program announcement PAR-03-121]. http://grants2.
nih.gov/grants/guide/pa-files/PAR-03-121.html.
28. Burcelin, R., Crivelli, V., Dacosta, A., Roy-Tirelli, A.,
and Thorens, B. 2002. Heterogeneous metabolic
adaptation of C57BL/6J mice to high-fat diet. Am.
J. Physiol. Endocrinol. Metab. 282:E834–E842.
29. Ozcan, U., et al. 2004. Endoplasmic reticulum
stress links obesity, insulin action, and type 2 diabetes. Science. 306:457–461.
30. Randle, P.J., Garland, P.B., Hales, C.N., and Newsholme, E.A. 1963. The glucose fatty-acid cycle. Its
role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:785–789.
31. Rothman, D.L., Shulman, R.G., and Shulman, G.I.
1992. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence
for reduced insulin-dependent muscle glucose
transport or phosphorylation activity in noninsulin-dependent diabetes mellitus. J. Clin. Invest.
89:1069–1075.
32. Shulman, G.I. 2004. Unraveling the cellular mechanism of insulin resistance in humans: new insights
from magnetic resonance spectroscopy. Physiology
(Bethesda). 19:183–190.
33. Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., and
Shulman, G.I. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients
with type 2 diabetes. N. Engl. J. Med. 350:664–671.
34. Matthews, D.R. 1999. The natural history of diabetes-related complications: the UKPDS experience.
United Kingdom Prospective Diabetes Study. Diabetes Obes. Metab. 1(Suppl. 2):S7–S13.
35. Redondo, M.J., Fain, P.R., and Eisenbarth, G.S.
2001. Genetics of type 1A diabetes. Recent Prog.
Horm. Res. 56:69–89.
36. Beck-Nielsen, H., Vaag, A., Poulsen, P., and Gaster,
M. 2003. Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects — experiences from relatives and twin studies. Best Pract.
Res. Clin. Endocrinol. Metab. 17:445–467.
37. Florez, J.C., Hirschhorn, J., and Altshuler, D. 2003.
The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits.

1438

Annu. Rev. Genomics Hum. Genet. 4:257–291.
38. Poulsen, P., Kyvik, K.O., Vaag, A., and Beck-Nielsen,
H. 1999. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance — a population-based twin study. Diabetologia.
42:139–145.
39. Mills, G.W., et al. 2004. Heritability estimates for
beta cell function and features of the insulin resistance syndrome in UK families with an increased
susceptibility to type 2 diabetes. Diabetologia.
47:732–738.
40. Hanson, R.L., et al. 2001. Family and genetic studies of indices of insulin sensitivity and insulin
secretion in Pima Indians. Diabetes Metab. Res. Rev.
17:296–303.
41. Austin, M.A., et al. 2004. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese Americans. Diabetes. 53:1166–1169.
42. Henkin, L., et al. 2003. Genetic epidemiology of
insulin resistance and visceral adiposity. The IRAS
Family Study design and methods. Ann. Epidemiol.
13:211–217.
43. Perusse, L., et al. 2000. Familial aggregation of
amount and distribution of subcutaneous fat and
their responses to exercise training in the HERITAGE family study. Obes. Res. 8:140–150.
44. McCarthy, M.I. 2003. Growing evidence for diabetes susceptibility genes from genome scan data.
Curr. Diab. Rep. 3:159–167.
45. Musso, C., et al. 2004. Clinical course of genetic
diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective.
Medicine (Baltimore). 83:209–222.
46. Maassen, J.A., et al. 2004. Mitochondrial diabetes:
molecular mechanisms and clinical presentation.
Diabetes. 53(Suppl. 1):S103–S109.
47. Permutt, M.A., and Hattersley, A.T. 2000. Searching
for type 2 diabetes genes in the post-genome era.
Trends Endocrinol. Metab. 11:383–393.
48. Shih, D.Q., and Stoffel, M. 2002. Molecular etiologies of MODY and other early-onset forms of diabetes. Curr. Diab. Rep. 2:125–134.
49. Fajans, S.S., Bell, G.I., and Polonsky, K.S. 2001.
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.
N. Engl. J. Med. 345:971–980.
50. Ledermann, H.M. 1995. Maturity-onset diabetes of
the young (MODY) at least ten times more common in Europe than previously assumed? [letter.]
Diabetologia. 38:1482.
51. Jeong, H., Tombor, B., Albert, R., Oltvai, Z.N., and
Barabasi, A.L. 2000. The large-scale organization of
metabolic networks. Nature. 407:651–654.
52. Barabasi, A.L., and Oltvai, Z.N. 2004. Network biology: understanding the cell’s functional organization. Nat. Rev. Genet. 5:101–113.
53. Almaas, E., Kovacs, B., Vicsek, T., Oltvai, Z.N.,
and Barabasi, A.L. 2004. Global organization of
metabolic fluxes in the bacterium Escherichia coli.
Nature. 427:839–843.
54. Krauthammer, M., Kaufmann, C.A., Gilliam,
T.C., and Rzhetsky, A. 2004. Molecular triangulation: bridging linkage and molecular-network
information for identifying candidate genes in
Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A.
101:15148–15153.
55. Cudworth, A.G., and Woodrow, J.C. 1975. Evidence
for HL-A-linked genes in “juvenile” diabetes mellitus. Br. Med. J. 3:133–135.
56. John, S., et al. 2004. Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am.
J. Hum. Genet. 75:54–64.
57. Spielman, R.S., McGinnis, R.E., and Ewens, W.J.
1993. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet.
52:506–516.

The Journal of Clinical Investigation

http://www.jci.org

Volume 115

58. Cox, N.J., and Spielman, R.S. 1989. The insulin
gene and susceptibility to IDDM. Genet. Epidemiol.
6:65–69.
59. Concannon, P., et al. 1998. A second-generation
screen of the human genome for susceptibility to
insulin-dependent diabetes mellitus. Nat. Genet.
19:292–296.
60. Cox, N.J., et al. 2001. Seven regions of the genome
show evidence of linkage to type 1 diabetes in a
consensus analysis of 767 multiplex families. Am.
J. Hum. Genet. 69:820–830.
61. Bottini, N., et al. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I
diabetes. Nat. Genet. 36:337–338.
62. Begovich, A.B., et al. 2004. A missense singlenucleotide polymorphism in a gene encoding a
protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet.
75:330–337.
63. Kyogoku, C., et al. 2004. Genetic association of
the R620W polymorphism of protein tyrosine
phosphatase PTPN22 with human SLE. Am. J.
Hum. Genet. 75:504–507.
64. Watanabe, R.M., et al. 1999. Genome wide linkage analysis of type 2 diabetes-related quantitative
traits in the FUSION study. Diabetes Abstract Book.
48(Suppl. 1):A46.
65. Hanson, R.L., and Knowler, W.C. 2003. Quantitative trait linkage studies of diabetes-related traits.
Curr. Diab. Rep. 3:176–183.
66. Rich, S.S., et al. 2004. Identification of quantitative trait loci for glucose homeostasis: the Insulin
Resistance Atherosclerosis Study (IRAS) Family
Study. Diabetes. 53:1866–1875.
67. Valdar, W.S., Flint, J., and Mott, R. 2003. QTL finemapping with recombinant-inbred heterogeneous
stocks and in vitro heterogeneous stocks. Mamm.
Genome. 14:830–838.
68. Altshuler, D., et al. 2000. The common PPARg
prol12ala polymorphism is associated with decreased
risk of type 2 diabetes. Nat. Genet. 26:76–80.
69. Barratt, B.J., et al. 2004. Remapping the insulin
gene/IDDM2 locus in type 1 diabetes. Diabetes.
53:1884–1889.
70. Weedon, M.N., et al. 2003. Meta-analysis and a
large association study confirm a role for calpain10 variation in type 2 diabetes susceptibility. Am. J.
Hum. Genet. 73:1208–1212.
71. Ueda, H., et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 423:506–511.
72. Horikawa, Y., et al. 2000. Genetic variation in the
calpain 10 gene (CAPN10) is associated with type
2 diabetes mellitus [erratum 2000, 26:502]. Nat.
Genet. 26:163–175.
73. Silander, K., et al. 2004. Genetic variation near the
hepatocyte nuclear factor-4α gene predicts susceptibility to type 2 diabetes. Diabetes. 53:1141–1149.
74. Love-Gregory, L.D., et al. 2004. A common polymorphism in the upstream promoter region of the
hepatocyte nuclear factor-4α gene on chromosome
20q is associated with type 2 diabetes and appears
to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes. 53:1134–1140.
75. Love-Gregory, L., et al. 2003. E23K single nucleotide polymorphism in the islet ATP-sensitive
potassium channel gene (Kir6.2) contributes as
much to the risk of type II diabetes in Caucasians
as the PPARgamma Pro12Ala variant. Diabetologia.
46:136–137.
76. Gloyn, A.L., et al. 2003. Large-scale association
studies of variants in genes encoding the pancreatic
beta-cell KATP channel subunits Kir6.2 (KCNJ11)
and SUR1 (ABCC8) confirm that the KCNJ11 E23K
variant is associated with type 2 diabetes. Diabetes.
52:568–572.
77. Lausen, J., et al. 2000. Naturally occurring mutations in the human HNF4α gene impair the func-

Number 6

June 2005

Downloaded on June 9, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/24758

review series
tion of the transcription factor to a varying degree.
Nucleic Acids Res. 28:430–437.
78. Ghosh, S., et al. 1999. Type 2 diabetes: evidence for
linkage on chromosome 20 in 716 Finnish affected
sib pairs. Proc. Natl. Acad. Sci. U. S. A. 96:2198–2203.
79. Thomas, H., et al. 2001. A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young. Hum. Mol. Genet. 10:2089–2097.
80. Hansen, S.K., et al. 2002. Genetic evidence that
HNF-1α-dependent transcriptional control of
HNF-4α is essential for human pancreatic β cell
function. J. Clin. Invest. 110:827–833. doi:10.1172/
JCI200215085.
81. Weedon, M.N., et al. 2004. Common variants of the
hepatocyte nuclear factor-4 P2 promoter are associated with type 2 diabetes in the U.K. population.
Diabetes. 53:3002–3006.
82. Shepherd, M., and Hattersley, A.T. 2004. ‘I don’t
feel like a diabetic any more’: the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Clin.
Med. 4:144–147.
83. Bentley, D.R. 2004. Genomes for medicine. Nature.
429:440–445.
84. Bell, J. 2004. Predicting disease using genomics.
Nature. 429:453–456.
85. Pearson, E.R., et al. 2003. Genetic cause of hyperglycaemia and response to treatment in diabetes.
Lancet. 362:1275–1281.
86. Sagen, J.V., et al. 2004. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2:
patient characteristics and initial response to sulfonylurea therapy. Diabetes. 53:2713–2718.
87. Collins, F.S. 2004. The case for a US prospective
cohort study of genes and environment. Nature.
429:475–477.
88. Whelton, P.K., and Gordis, L. 2000. Epidemiology
of clinical medicine. Epidemiol. Rev. 22:140–144.
89. Altshuler, J.S., and Altshuler, D. 2004. Organizational challenges in clinical genomic research.
Nature. 429:478–481.
90. Yamagata, K., et al. 1996. Mutations in the hepatocyte
nuclear factor-4α gene in maturity-onset diabetes
of the young (MODY1). Nature. 384:458–460.
91. Lindner, T., et al. 1997. Hepatic function in a
family with a nonsense mutation (R154X) in the
hepatocyte nuclear factor-4α/MODY1 gene. J. Clin.
Invest. 100:1400–1405.
92. Gidh-Jain, M., et al. 1993. Glucokinase mutations

associated with non-insulin-dependent (type 2)
diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. Proc. Natl. Acad. Sci. U. S. A. 90:1932–1936.
93. Barrio, R., et al. 2002. Nine novel mutations in
maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J. Clin. Endocr.
Metab. 87:2532–2539.
94. Yamagata, K., et al. 1996. Mutations in the hepatocyte
nuclear factor-1α gene in maturity-onset diabetes of
the young (MODY3). Nature. 384:455–457.
95. Stoffers, D.A., Ferrer, J., Clarke, W.L., and Habener, J.F. 1997. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1 [letter]. Nat. Genet.
17:138–141.
96. Lindner, T.H., et al. 1999. A novel syndrome of
diabetes mellitus, renal dysfunction and genital
malformation associated with a partial deletion
of the pseudo-POU domain of hepatocyte nuclear
factor-1-beta. Hum. Mol. Genet. 8:2001–2008.
97. Horikawa, Y., et al. 1997. Mutation in hepatocyte
nuclear factor-1-beta gene (TCF2) associated with
MODY [letter]. Nat. Genet. 17:384–385.
98. Malecki, M.T., et al. 1999. Mutations in NEUROD1
are associated with the development of type 2 diabetes mellitus. Nat. Genet. 23:323–328.
99. Davies, J.L., et al. 1994. A genome-wide search for
human type 1 diabetes susceptibility genes. Nature.
371:130–136.
100. Hashimoto, L., et al. 1994. Genetic mapping of a
susceptibility locus for insulin-dependent diabetes
mellitus on chromosome 11q. Nature. 371:161–164.
101. Mein, C.A., et al. 1998. A search for type 1 diabetes
susceptibility genes in families from the United
Kingdom. Nat. Genet. 19:297–300.
102. Donner, H., et al. 1997. CTLA4 Alanine-17 confers
genetic susceptibility to Graves’ disease and to
type 1 diabetes mellitus. J. Clin. Endocrinol. Metab.
82:143–146.
103. Marron, M.P., et al. 1997. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4
polymorphisms in multiple ethnic groups. Hum.
Mol. Genet. 6:1275–1282.
104. Smyth, D., et al. 2004. Replication of an association
between the lymphoid tyrosine phosphatase locus
(LYP/PTPN22) with type 1 diabetes, and evidence
for its role as a general autoimmunity locus. Diabetes. 53:3020–3023.
105. Inoue, H., et al. 1996. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with

The Journal of Clinical Investigation

http://www.jci.org

Volume 115

NIDDM in Caucasians. Diabetes. 45:825–831.
106. Hani, E.H., et al. 1997. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in
morbid obesity among French Caucasians. Diabetes. 46:688–694.
107. del Bosque-Plata, L., et al. 2004 Association of the
calpain-10 gene with type 2 diabetes mellitus in a
Mexican population. Mol. Genet. Metab. 81:122–126.
108. Hager, J., et al. 1995. A missense mutation in the
glucagon receptor gene is associated with noninsulin-dependent diabetes mellitus. Nat. Genet.
9:299–304.
109. Gough, S.C., et al. 1995. Mutation of the glucagon
receptor gene and diabetes mellitus in the UK:
association or founder effect? Hum. Mol. Genet.
4:1609–1612.
110. Chiu, K.C., et al. 1992. A genetic marker at the
glucokinase gene locus for type 2 (non-insulindependent) diabetes mellitus in Mauritian Creoles.
Diabetologia. 35:632–638.
111. McCarthy, M.I., et al. 1994. Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in a cohort of elderly Finnish men. Diabetes
Med. 11:198–204
112.Hani, E.H., et al. 1998. Missense mutations in
the pancreatic islet beta cell inwardly rectifying
K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type
II diabetes mellitus in Caucasians. Diabetologia.
41:1511–1115.
113. Gloyn, A.L., et al. 2001. Association studies of variants in promoter and coding regions of beta-cell
ATP-sensitive K-channel genes SUR1 and Kir6.2
with Type 2 diabetes mellitus (UKPDS 53). Diabetes
Med. 18:206–212.
114. Deeb, S.S., et al. 1998. A Pro12Ala substitution in
PPARgamma2 associated with decreased receptor
activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284–287.
115. Hara, K., et al. 2000. The Pro12Ala polymorphism in
PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271:212–216.
116. Li, S.R., Baroni, M.G., Oelbaum, R.S., Stock, J., and
Galton, D.J. 1988. Association of genetic variant of
the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet. 2:368–370.
117. Tao, T., et al. 1995. HepG2/erythrocyte glucose
transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in
Japanese subjects. Diabetologia. 38:942–947.

Number 6

June 2005

1439

